Feasibility · NSCLC · Phase II–III
Non-small-cell lung cancer (NSCLC) trial feasibility, cited to its source.
NSCLC is one of the most actively studied indications, with feasibility dominated by molecular sub-segmentation (EGFR, ALK, KRAS G12C, PD-L1 status). The practical question is rarely "how many lung-cancer patients" but "how many of the right molecular subtype are reachable at non-saturated sites."
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
- Molecular subtype gating can shrink the eligible population by an order of magnitude versus all-NSCLC.
- Heavy competition for biomarker-positive patients inflates apparent site availability.
- Line-of-therapy eligibility (1L vs pretreated) materially changes reachability.
- Strong approval precedent supports directional PTRS priors for established mechanisms.
Benchmarks · snapshot 2026-06-14
The numbers, each cited.
1,071
Recruiting interventional trials, worldwide
Source: ClinicalTrials.gov — cond: NSCLC, interventional, recruiting
493
Recruiting interventional trials, United States
Source: ClinicalTrials.gov — cond: NSCLC, interventional, recruiting, US
7,045
Interventional trials registered, all statuses
Source: ClinicalTrials.gov — cond: NSCLC, interventional
Grounded in public data
For nsclc, the verdict draws primarily on ClinicalTrials.gov, AACT, PubMed, FDA, ChEMBL — every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. See the full data sources and compare other indications.
See a cited verdict for nsclc.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.